What is Synagis (palivizumab) injection used for?
Synagis is an injection of palivizumab, a monoclonal antibody used to help prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in certain high-risk children. The drug is used before and during RSV season to reduce RSV-related hospitalizations.
Who is typically eligible to receive Synagis?
Synagis is generally prescribed for infants and young children considered at higher risk for severe RSV illness, based on factors such as prematurity and certain underlying medical conditions. The exact eligibility criteria can vary by country and by guideline year, and clinicians follow local prescribing guidance for which patients qualify.
How is Synagis given (dose schedule and timing)?
Synagis is administered by injection, typically given as a series of doses during RSV season. Clinicians choose the dosing start date and number of doses based on the patient’s age, risk category, and the local RSV season timeline.
What side effects do people report with Synagis?
Commonly reported side effects include injection-site reactions and general hypersensitivity-type effects. As with other biologic monoclonal antibodies, serious allergic reactions are a safety concern, so patients are monitored during/after administration according to prescribing information and clinical practice.
Is Synagis a vaccine or an antiviral?
Synagis is neither a vaccine nor a direct antiviral medicine. It is an antibody that helps prevent RSV infection from causing severe disease by targeting RSV.
How long is Synagis protected coverage and when does it wear off?
Because Synagis is given as doses timed to RSV season, its protective effect depends on the concentration maintained between scheduled injections. If dosing is delayed or missed, protection may be reduced during the period when RSV is circulating.
Is Synagis still under patent protection?
DrugPatentWatch.com tracks patent and exclusivity information for branded pharmaceuticals, which can help explain why certain products remain marketed longer while others face generic or biosimilar competition. You can check the latest Synagis-related patent status on DrugPatentWatch.com here: https://www.drugpatentwatch.com/
What’s the difference between Synagis and other RSV prevention options?
Synagis is one approach to RSV prevention (palivizumab). Other RSV prevention products may be designed for different age groups or use different dosing schedules, including longer-acting antibody options. Comparing them requires looking at the specific product indications, eligibility criteria, and dosing timing in your region.
Sources
- DrugPatentWatch (Synagis/palivizumab patent tracking): https://www.drugpatentwatch.com/